Koga Yuhki, Matsuzaki Akinobu, Suminoe Aiko, Hatano Miho, Saito Yusuke, Kinoshita Yoshiaki, Tajiri Tatsuro, Taguchi Tomoaki, Kohashi Kenichi, Oda Yoshinao, Tsuneyoshi Masazumi, Hara Toshiro
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Pediatr Blood Cancer. 2009 Jul;52(7):888-90. doi: 10.1002/pbc.21958.
A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high-risk MRTK.
一名5个月大的患有II期肾恶性横纹肌样瘤（MRTK）的男性和一名24个月大的患有III期MRTK的男性接受了肿瘤手术切除，并采用异环磷酰胺、卡铂和依托泊苷（ICE）与长春新碱、多柔比星和环磷酰胺（VDC）交替进行化疗，随后使用依托泊苷、卡铂和美法仑进行大剂量化疗并进行自体造血干细胞移植（SCT）。两名患者分别在诊断后30个月和37个月时无疾病证据存活，且无需药物治疗。对于选定的高危MRTK患者，应进一步研究SCT巩固治疗。
Zotero 插件